Yuki Kojima
YOU?
Author Swipe
View article: Slow‐Growing Whitish Flat Elevated Lesion of the Esophagus
Slow‐Growing Whitish Flat Elevated Lesion of the Esophagus Open
View article: A Case of Pancreatolithiasis Treated by a Combination of Extracorporeal Shock Wave Lithotripsy, Metallic Stent Placement, and Radiofrequency Ablation
A Case of Pancreatolithiasis Treated by a Combination of Extracorporeal Shock Wave Lithotripsy, Metallic Stent Placement, and Radiofrequency Ablation Open
View article: Clinical applications of cell-free DNA-based liquid biopsy analysis
Clinical applications of cell-free DNA-based liquid biopsy analysis Open
Liquid biopsies, particularly those involving circulating tumor DNA (ctDNA) from patient blood, have emerged as crucial and minimally invasive adjuncts to standard tissue-based testing. ctDNA testing enables the identification of actionabl…
View article: Baseline risk variability by eligibility criteria in Cohort 1 of the monarchE trial for high-risk HR-positive, HER2-negative breast cancer
Baseline risk variability by eligibility criteria in Cohort 1 of the monarchE trial for high-risk HR-positive, HER2-negative breast cancer Open
View article: <scp>cGAS</scp>–<scp>STING</scp> Pathway Activation Enhances Antitumor Effect of Talaporfin Photodynamic Therapy Through <scp>ROS</scp> Production
<span>cGAS</span>–<span>STING</span> Pathway Activation Enhances Antitumor Effect of Talaporfin Photodynamic Therapy Through <span>ROS</span> Production Open
Photodynamic therapy (PDT) is a noninvasive anticancer treatment that uses a photosensitizer and light irradiation. PDT generates reactive oxygen species (ROS), thereby inducing tumor cell death. Stimulation of the interferon gene (STING) …
View article: Immediate and Short-Term Intraocular Pressure Changes Following Intravitreal Injection and Associated Factors
Immediate and Short-Term Intraocular Pressure Changes Following Intravitreal Injection and Associated Factors Open
Objectives: To evaluate the immediate and short-term changes in intraocular pressure (IOP) following intravitreal injection (IVI) of anti-vascular endothelial growth factor (VEGF) agents and to identify the clinical and procedural factors …
View article: POS0423-PARE TRANSFORMING PATIENT ORGANIZATIONS THROUGH EDUCATION & COLLABORATION IN JAPAN
POS0423-PARE TRANSFORMING PATIENT ORGANIZATIONS THROUGH EDUCATION & COLLABORATION IN JAPAN Open
View article: Abstract 2034: Investigation of TROP2 expression and immune microenvironment in ovarian clear cell carcinoma
Abstract 2034: Investigation of TROP2 expression and immune microenvironment in ovarian clear cell carcinoma Open
Background: Ovarian clear cell carcinoma (OCCC) is a rare subtype of ovarian cancer, with a higher incidence in East Asia compared to Western countries and a tendency to affect younger individuals. OCCC has poor prognosis due to its low se…
View article: Mesenchymal stem cell-derived small extracellular vesicles as a delivery vehicle of oncolytic reovirus
Mesenchymal stem cell-derived small extracellular vesicles as a delivery vehicle of oncolytic reovirus Open
This study demonstrates that sEVs-reo can address key challenges associated with oncolytic virotherapy. These findings support potential of sEVs as a novel and effective DDS for reovirus in colon cancer treatment, while offering a versatil…
View article: Germline Pathogenic Variants and Clinical Outcomes in Asian Patients With Breast Cancer
Germline Pathogenic Variants and Clinical Outcomes in Asian Patients With Breast Cancer Open
Despite the importance of genetic testing for risk assessment and treatment in breast cancer, the prognostic impact of germline pathogenic variants (PVs), especially in Asian populations, is unclear. We assessed the impact of germline PVs …
View article: Beta-blockers for electroconvulsive therapy: A systematic review and meta-analysis
Beta-blockers for electroconvulsive therapy: A systematic review and meta-analysis Open
Electroconvulsive therapy (ECT) is an established treatment for various mental disorders. However, ECT can induce significant haemodynamic fluctuations, raising safety concerns. This systematic review and meta-analysis aimed to evaluate th…
View article: TFE3-rearranged perivascular epithelioid cell tumors of the head and neck with rare fusion partners: clues to the differential diagnosis between benign and malignant tumors
TFE3-rearranged perivascular epithelioid cell tumors of the head and neck with rare fusion partners: clues to the differential diagnosis between benign and malignant tumors Open
View article: Supplementary Figure S1 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Figure S1 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
MASTER KEY PROJECT
View article: Supplementary Figure S5 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Figure S5 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
Correlation between the MDM2 copy number and tumor shrinkage
View article: Supplementary Figure S4B from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Figure S4B from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
Anti-tumor activity
View article: Supplementary Table S5A from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Table S5A from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
Whole-exome sequencing and RNA sequencing analyses of archived tumor tissue samples
View article: Supplementary Table S5B from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Table S5B from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
Whole-exome sequencing and RNA sequencing analyses of tumor tissue samples at pre-and post-treatment
View article: Supplementary Table S5B from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Table S5B from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
Whole-exome sequencing and RNA sequencing analyses of tumor tissue samples at pre-and post-treatment
View article: Supplementary Table S2 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Table S2 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
Patient characteristics
View article: Supplementary Table S7 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Table S7 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
Criteria for modifying treatment
View article: Supplementary Table S1 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Table S1 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
Representativeness of study participant
View article: Supplementary Table S1 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Table S1 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
Representativeness of study participant
View article: Supplementary Table S3A-B from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Table S3A-B from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
Pharmacokinetics
View article: Supplementary Table S4 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Table S4 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
Progression-free survival ratio
View article: Supplementary Figure S2 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Figure S2 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
Pharmacokinetics
View article: Supplementary Figure S4A from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Figure S4A from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
Anti-tumor activity
View article: Supplementary Figure S3 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Figure S3 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
Supplementary Dosing schedule in 11 patients
View article: Supplementary Table S6 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Table S6 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
Targeted sequencing analysis of cell-free DNA samples
View article: Supplementary Figure S6 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Figure S6 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
Study design
View article: Supplementary Figure S6 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Figure S6 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
Study design